Fred R. Hirsch

PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project

Fred R. Hirsch, Abigail McElhinny, Dave Stanforth et al. · Journal of Thoracic Oncology · 2016 · 1.3K citations · Full text

Medicine, Cancer Biology, Oncology +14

Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology

Neal I. Lindeman, Philip T. Cagle, Dara L. Aisner et al. · Archives of Pathology & Laboratory Medicine · 2018 · 931 citations · Full text

Medicine, Oncology, Pathology +17

PD-L1 Immunohistochemistry Comparability Study in Real-Life Clinical Samples: Results of Blueprint Phase 2 Project

Ming‐Sound Tsao, Keith M. Kerr, Mark Kockx et al. · Journal of Thoracic Oncology · 2018 · 807 citations · Full text

Medicine, Pathology, Immunopathology +6

A Prospective, Multi-institutional, Pathologist-Based Assessment of 4 Immunohistochemistry Assays for PD-L1 Expression in Non–Small Cell Lung Cancer

David L. Rimm, Gang Han, Janis M. Taube et al. · JAMA Oncology · 2017 · 762 citations

Medicine, Oncology, Pathology +17

Molecular Predictors of Outcome With Gefitinib in a Phase III Placebo-Controlled Study in Advanced Non–Small-Cell Lung Cancer

Fred R. Hirsch, Marileila Varella‐Garcia, Paul A. Bunn et al. · Journal of Clinical Oncology · 2006 · 703 citations · Full text

Medicine, Molecular Genetics, Oncology +17